Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DOXORUBICIN Cause Condition aggravated? 985 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 985 reports of Condition aggravated have been filed in association with DOXORUBICIN (Doxorubicin Hydrochloride). This represents 1.2% of all adverse event reports for DOXORUBICIN.

985
Reports of Condition aggravated with DOXORUBICIN
1.2%
of all DOXORUBICIN reports
319
Deaths
437
Hospitalizations

How Dangerous Is Condition aggravated From DOXORUBICIN?

Of the 985 reports, 319 (32.4%) resulted in death, 437 (44.4%) required hospitalization, and 107 (10.9%) were considered life-threatening.

Is Condition aggravated Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DOXORUBICIN. However, 985 reports have been filed with the FAERS database.

What Other Side Effects Does DOXORUBICIN Cause?

Febrile neutropenia (8,844) Off label use (7,858) Disease progression (6,165) Neutropenia (5,891) Drug ineffective (4,598) Pyrexia (3,697) Thrombocytopenia (3,638) Anaemia (3,601) Product use in unapproved indication (3,502) Nausea (2,925)

What Other Drugs Cause Condition aggravated?

TOFACITINIB (16,925) INFLIXIMAB (16,616) DUPILUMAB (16,459) ETANERCEPT (15,897) METHOTREXATE (14,938) ADALIMUMAB (13,527) PREDNISONE (10,751) INFLIXIMAB-DYYB (10,275) HYDROXYCHLOROQUINE (8,848) RITUXIMAB (8,627)

Which DOXORUBICIN Alternatives Have Lower Condition aggravated Risk?

DOXORUBICIN vs DOXYCYCLINE DOXORUBICIN vs DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYCYCLINE\DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYLAMINE DOXORUBICIN vs DOXYLAMINE\PYRIDOXINE

Related Pages

DOXORUBICIN Full Profile All Condition aggravated Reports All Drugs Causing Condition aggravated DOXORUBICIN Demographics